Oxidized metabolites of linoleic acid as biomarkers of liver injury in nonalcoholic steatohepatitis

References

• Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346, 1221–1231 (2002).
   Google Scholar
• Szczepaniak LS, Nurenberg P, Leonard D et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am. J. Physiol. Endocrinol. Metab. 288, e462–e468 (2005).
   Google Scholar
• Mencin AA, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Pediatr. Clin. North Am. 201(58), 1375–1392 (2011).
   Google Scholar
• Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 118, 1388–1393 (2006).
   Google Scholar
• Argo CK, Northup PG, Al‑Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non‑alcoholic steatohepatitis. J. Hepatol. 51, 371–379 (2009).
   Google Scholar
• Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51, 1972–1978 (2010).
   Google Scholar
• Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51, 1820–1832 (2010).
   Google Scholar
• Burgert TS, Taksali SE, Dziura J et al. Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J. Clin. Endocrinol. Metab. 91, 4287–4294 (2006).
   Google Scholar
• Cali AM, De Oliveira AM, Kim H et al. Glucose dysregulation and hepatic steatosis in obese adolescents: is there a link? Hepatology 49, 1896–1903 (2009).
   Google Scholar
• Cali AM, Zern TL, Taksali SE et al. Intrahepatic fat accumulation and alterations in lipoprotein composition in obese adolescents: a perfect proatherogenic state. Diabetes Care 30, 3093–3098 (2007).
   Google Scholar
• D’Adamo E, Cali AM, Weiss R et al. The central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents. Diabetes Care 33, 1817–1822 (2010). ▪▪ Shows that the effect of fatty liver on insulin resistance is independent of visceral and intramuscular fat accumulation.
   Google Scholar
• Fierbinteanu‑Braticevici C, Negreanu L, Tarantino G. Is fatty liver always benign and should not consequently be treated? J. Physiol. Pharmacol. 64(1), 3–9 (2013).
   Google Scholar
• Tarantino G, Conca P, Riccio A et al. Enhanced serum concentrations of transforming growth factor‑beta1 in simple fatty liver: is it really benign? J. Transl. Med. 6, 72 (2008).
   Google Scholar
• Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 332, 1519–1523 (2011).
   Google Scholar
• Redgrave TG. Formation of cholesteryl esterrich particulate lipid during metabolism of chylomicrons. J. Clin. Invest. 49, 465–471 (1970).
   Google Scholar
• Cortez‑Pinto H, Jesus L, Barros H, Lopes C, Moura MC, Camilo ME. How different is the dietary pattern in non‑alcoholic steatohepatitis patients? Clin. Nutr. 25, 816–823 (2006).
   Google Scholar
• Toshimitsu K, Matsuura B, Ohkubo I et al. Dietary habits and nutrient intake in nonalcoholic steatohepatitis. Nutrition 23, 46–52 (2007).
   Google Scholar
• Li Y, Chen D. The optimal dose of omega‑3 supplementation for non‑alcoholic fatty liver disease. J. Hepatol. 57, 468–469 (2012).
   Google Scholar
• Araya J, Rodrigo R, Videla LA et al. Increase in long‑chain polyunsaturated fatty acid n‑6/n‑3 ratio in relation to hepatic steatosis in patients with non‑alcoholic fatty liver disease. Clin. Sci. 106, 635–643 (2004).
   Google Scholar
• Puri P, Baillie RA, Wiest MM et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46, 1081–1090 (2007).
   Google Scholar
• Eaton SB, Eaton SB 3rd, Sinclair AJ, Cordain L, Mann NJ. Dietary intake of long‑chain polyunsaturated fatty acids during the paleolithic. World Rev. Nutr. Diet 83, 12–23 (1998).
   Google Scholar
• Simopoulos AP. Overview of evolutionary aspects of omega‑3 fatty acids in the diet. World Rev. Nutr. Diet 83, 1–11 (1998).
   Google Scholar
• Sanders TA. Polyunsaturated fatty acids in the food chain in Europe. Am. J. Clin. Nutr. 71(Suppl. 1), S176–S178 (2000).
   Google Scholar
• Mozaffarian D, Wu JH. Omega‑3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J. Am. Coll. Cardiol. 58, 2047–2067 (2011).
   Google Scholar
• González‑Périz A, Horrillo R, Ferré N et al. Obesity‑induced insulin resistance and hepatic steatosis are alleviated by omega‑3 fatty acids: a role for resolvins and protectins. FASEB J. 23, 1946–1957 (2009).
   Google Scholar
• Masterton GS, Plevris JN, Hayes PC. Review article: omega‑3 fatty acids – a promising novel therapy for non‑alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 31, 679–692 (2010).
   Google Scholar
• Sekiya M, Yahagi N, Matsuzaka T et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP‑1 suppression. Hepatology 38, 1529–1539 (2003).
   Google Scholar
• Levy JR, Clore JN, Stevens W. Dietary n‑3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology 39, 608–616 (2004).
   Google Scholar
• Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator‑activated receptor alpha mediates the adaptive response to fasting. J. Clin. Invest. 103, 1489–1498 (1999).
   Google Scholar
• Cussons AJ, Watts GF, Mori TA, Stuckey BG. Omega‑3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J. Clin. Endocrinol. Metab. 94, 3842–3848 (2009).
   Google Scholar
• Nobili V, Bedogni G, Alisi A et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non‑alcoholic fatty liver disease: double‑blind randomised controlled clinical trial. Arch. Dis. Child. 96, 350–353 (2011).
   Google Scholar
• Parker HM, Johnson NA, Burdon CA, Cohn JS, O’Connor HT, George J. Omega‑3 supplementation and non‑alcoholic fatty liver disease: a systematic review and metaanalysis. J. Hepatol. 56, 944–951 (2012).
   Google Scholar
• Narasimhan S, Gokulakrishnan K, Sampathkumar R et al. Oxidative stress is independently associated with non‑alcoholic fatty liver disease (NAFLD) in subjects with and without Type 2 diabetes. Clin. Biochem. 43, 815–821 (2010).
   Google Scholar
• Byrne CD. Fatty liver: role of inflammation and fatty acid nutrition. Prostaglandins Leukot. Essent. Fatty Acids 82, 265–271 (2010).
   Google Scholar
• Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99, 1497–1502 (2004).
   Google Scholar
• Yesilova Z, Yaman H, Oktenli C et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am. J. Gastroenterol. 100, 850–855 (2005).
   Google Scholar
• Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatoshepatitis. Free Radic. Biol. Med. 52, 59–69 (2012).
   Google Scholar
• Tarantino G, Finelli C, Colao A, Capone D, Tarantino M, Grimaldi E et al. Are hepatic steatosis and carotid intima media thickness associated in obese patients with normal or slightly elevated gamma‑glutamyl‑transferase? J. Transl. Med. 10, 50 (2012).
   Google Scholar
• Tarantino G, Scopacasa F, Colao A et al. Serum Bcl‑2 concentrations in overweightobese subjects with nonalcoholic fatty liver disease. World J. Gastroenterol. 17, 5280–5288 (2011).
   Google Scholar
• Reinaud O, Delaforge M, Boucher JL, Rocchiccioli F, Mansuy D. Oxidative metabolism of linoleic acid by human leukocytes. Biochem. Biophys. Res. Commun. 161, 883–891 (1989).
   Google Scholar
• Engels F, Willems H, Nijkamp FP. Cyclooxygenase‑catalyzed formation of 9‑hydroxylinoleic acid by guinea pig alveolar macrophages under non‑stimulated conditions. FEBS Lett. 209, 249–253 (1986).
   Google Scholar
• Liu W, Yin H, Akazawa YO, Yoshida Y, Niki E, Porter NA. Ex vivo oxidation in tissue and plasma assays of hydroxyoctadecadienoates: Z,E/E,E stereoisomer ratios. Chem. Res. Toxicol. 23, 986–995 (2010).
   Google Scholar
• Spiteller G. Linoleic acid peroxidation – the dominant lipid peroxidation process in low density lipoprotein – and its relationship to chronic diseases. Chem. Phys. Lipids 95, 105–162 (1998).
   Google Scholar
• Barlic J, Murphy PM. An oxidized lipidperoxisome proliferator‑activated receptor gamma‑chemokine pathway in the regulation of macrophage–vascular smooth muscle cell adhesion. Trends Cardiovasc. Med. 17, 269–274 (2007).
   Google Scholar
• Belkner J, Wiesner R, Rathman J, Barnett J, Sigal E, Kühn H. Oxygenation of lipoproteins by mammalian lipoxygenases. Eur. J. Biochem. 213, 251–261 (1993).
   Google Scholar
• Brooks CJ, Harland WA, Steel G, Gilbert JD. Lipids of human atheroma: isolation of hydroxyoctadecadienoic acids from advanced aortal lesions. Biochim. Biophys. Acta 202, 563–566 (1970).
   Google Scholar
• Shibata N, Toi S, Shibata T et al. Immunohistochemical detection of 13(R) hydroxyoctadecadienoic acid in atherosclerotic plaques of human carotid arteries using a novel specific antibody. Acta Histochem. Cytochem. 42, 197–203 (2009).
   Google Scholar
• Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR gamma Cell 93, 229–240 (1998).
   Google Scholar
• Jira W, Spiteller G, Carson W, Schramm A. Strong increase in hydroxy fatty acids derived from linoleic acid in human low density lipoproteins of atherosclerotic patients. Chem. Phys. Lipids 91, 1–11 (1998).
   Google Scholar
• Kuhn H, Heydeck D, Hugou I, Gniwotta C. In vivo action of 15‑lipoxygenase in early stages of human atherogenesis. J. Clin. Invest. 99, 888–893 (1997).
   Google Scholar
• Feldstein AE, Lopez R, Tamimi TA et al. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J. Lipid Res. 51, 3046–3054 (2010). ▪▪ Provides evidence for an association between oxidized linoleic acid metabolite and nonalcoholic steatohepatitis.
   Google Scholar
• Böhm T, Berger H, Nejabat M et al. Foodderived peroxidized fatty acids may trigger hepatic inflammation: a novel hypothesis to explain steatohepatitis. J. Hepatol. pii: S0168‑8278(13)00280‑8 (2013).
   Google Scholar
• Zhang Y, Xue R, Zhang Z, Yang X, Shi H. Palmitic and linoleic acids induce ER stress and apoptosis in hepatoma cells. Lipids Health Dis. 11, 1 (2012).
   Google Scholar
• Ramsden CE, Ringel A, Feldstein AE et al. Lowering dietary linoleic acid reduces bioactive oxidized linoleic acid metabolites in humans. Prostaglandins Leukot. Essent. Fatty Acids 87, 135–141 (2012).
   Google Scholar
• Zein CO, Yerian LM, Gogate P et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebocontrolled trial. Hepatology 54, 1610–1619 (2011).
   Google Scholar
• Zein CO, Lopez R, Fu X et al. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology 56, 1291–1299 (2012). ▪▪ Provides evidence of the efficacy of pentoxifylline in lowering oxidized fatty acids.
   Google Scholar
• Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40, 1461–1465 (2008). ▪▪ First genome-wide association study for hepatic steatosis.
   Google Scholar
• Santoro N, Kursawe R, D’Adamo E et al. A common variant in the patatin‑like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 52, 1281–1290 (2010).
   Google Scholar
• Santoro N, Zhang CK, Zhao H et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 55, 781–789 (2012).
   Google Scholar
• Santoro N, Feldstein AE, Enoksson E et al. The association between hepatic fat content and liver injury in obese children and adolescents: effects of ethnicity, insulin resistance, and common gene variants. Diabetes Care 36, 1353–1360 (2013).
   Google Scholar
• Giudice EM, Grandone A, Cirillo G et al. The association of PNPLA3 variants with liver enzymes in childhood obesity is driven by the interaction with abdominal fat. PLoS ONE 6(11), e27933. (2011).
   Google Scholar
• Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat. Genet. 42, 21–23 (2010).
   Google Scholar
• Santoro N, Savoye M, Kim G et al. Hepatic fat accumulation is modulated by the interaction between the rs738409 variant in the PNPLA3 gene and the dietary omega6/omega3 PUFA intake. PLoS ONE 7(5), e37827 (2012). ▪▪ Shows the interaction between PNPLA3 rs738409 and the dietary n-6:n-3 polyunsaturated fatty acids ratio in modulating hepatic fat content and liver injury.
   Google Scholar
• Chamoun Z, Vacca F, Parton RG, Gruenberg J. PNPLA3/adiponutrin functions in lipid droplet formation. Biol. Cell. 105, 219–233 (2013).
   Google Scholar
• He S, McPhaul C, Li JZ et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J. Biol. Chem. 285, 6706–6715 (2010).
   Google Scholar
• Huang Y, He S, Li JZ et al. A feed‑forward loop amplifies nutritional regulation of PNPLA3. Proc. Natl Acad. Sci. USA 107, 7892–7897 (2010).
   Google Scholar
• Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J. Biol. Chem. 286, 37085–37093 (2011).
   Google Scholar
• Kumari M, Schoiswohl G, Chitraju C et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab. 15, 691–702 (2012).
   Google Scholar
• Li JZ, Huang Y, Karaman R et al. Chronic overexpression of PNPLA3 I148M in mouse liver causes hepatic steatosis. J. Clin. Invest. 122, 4130–4144 (2012). ▪▪ Shows an animal model recapitulating the human PNPLA3 rs738409 phenotype.
   Google Scholar